Career history of Mark K. Wedel
Former positions of Mark K. Wedel
Companies | Position | Start | End |
---|---|---|---|
ATHERONOVA INC. | Chief Tech/Sci/R&D Officer | 2012-12-17 | 2015-01-31 |
IONIS PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 2000-12-31 | 2008-08-17 |
Roche Innovation Center Copenhagen A/S
Roche Innovation Center Copenhagen A/S Pharmaceuticals: MajorHealth Technology Roche Innovation Center Copenhagen A/S discovers and develops drugs for the treatment of oncology, metabolic diseases, and infectious diseases. The firm manufactures a pipeline of drug candidates that act selectively on disease-related ribonucleic acid to provide patients with novel treatments for both rare and common diseases. It produces pre-clinical and clinical assets for the treatment of a range of diseases including oncology, metabolic diseases, and infectious diseases. The company was founded by Matts Lundwall and Mikael Ørum on January 1, 1998 and is headquartered in Horsholm, Denmark. | Chief Tech/Sci/R&D Officer | 2010-05-20 | - |
Scripps Clinic & Research Foundation | Chief Tech/Sci/R&D Officer | - | - |
US Department of Justice | Chief Tech/Sci/R&D Officer | - | - |
Training of Mark K. Wedel
Valparaiso University | Undergraduate Degree |
Thomas Jefferson School of Law | Graduate Degree |
The Johns Hopkins University School of Medicine | Doctorate Degree |
Statistics
International
United States | 8 |
Denmark | 2 |
Operational
Chief Tech/Sci/R&D Officer | 5 |
Undergraduate Degree | 1 |
Graduate Degree | 1 |
Sectoral
Health Technology | 4 |
Consumer Services | 4 |
Government | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 1 |
---|---|
IONIS PHARMACEUTICALS, INC. | Health Technology |
Private companies | 4 |
---|---|
Roche Innovation Center Copenhagen A/S
Roche Innovation Center Copenhagen A/S Pharmaceuticals: MajorHealth Technology Roche Innovation Center Copenhagen A/S discovers and develops drugs for the treatment of oncology, metabolic diseases, and infectious diseases. The firm manufactures a pipeline of drug candidates that act selectively on disease-related ribonucleic acid to provide patients with novel treatments for both rare and common diseases. It produces pre-clinical and clinical assets for the treatment of a range of diseases including oncology, metabolic diseases, and infectious diseases. The company was founded by Matts Lundwall and Mikael Ørum on January 1, 1998 and is headquartered in Horsholm, Denmark. | Health Technology |
US Department of Justice | Government |
Scripps Clinic & Research Foundation | |
AtheroNova, Inc.
AtheroNova, Inc. Pharmaceuticals: MajorHealth Technology AtheroNova, Inc. operates as biotechnology company. The company engages in the research and development, marketing, and sale of pharmaceutical preparations and pharmaceutical intellectual property. It develops intellectual property that uses certain pharmacological compounds for the treatment of atherosclerosis, which is the primary cause of various cardiovascular diseases. The company was founded by Giorgio Zadini and Filiberto Zadini in 1997 and is headquartered in Irvine, CA. | Health Technology |
- Stock Market
- Insiders
- Mark K. Wedel
- Experience